We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    04673942
Previous Study | Return to List | Next Study

A First in Human Study of AdAPT-001 in Subjects With Refractory Solid Tumors (BETA-PRIME)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04673942
Recruitment Status : Recruiting
First Posted : December 17, 2020
Last Update Posted : January 23, 2023
Sponsor:
Information provided by (Responsible Party):
EpicentRx, Inc.

Brief Summary:
This is the first clinical trial of AdAPT-001 for the treatment of cancer. AdAPT-001 is an oncolytic virus that is injected directly into the tumor. The purpose of this study is to find out the highest dose of AdAPT-001 that is safe and tolerable. This is the first step in studying whether it can be used to treat others with cancer in the future.

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Cancer Neoplasms Biological: AdAPT-001 Drug: Checkpoint Inhibitor, Immune Phase 1 Phase 2

Detailed Description:

This is a dose escalation protocol to determine, first and foremost, the safety, tolerability and feasibility of intratumoral administration of AdAPT-001.

The study has 3 parts. Different groups of patients will participate in each part.

PART 1: Dose Escalation Safety Run-In

During PART 1, all participants will be treated with AdAPT-001 as a single injection, one time. Participants will be assigned to different dose levels to find the highest dose of AdAPT-001 that is safe and tolerable.

PART 2: Dose Expansion Single-Agent

All participants in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.

PART 3: Expansion

Subjects will be assigned to the following two arms. If a checkpoint inhibitor is indicated for the subject, the subject may be enrolled on Arm 2 per investigator discretion, otherwise subjects may be enrolled on Arm 1.

Arm 1: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections.

Arm 2: Intratumoral administration of AdAPT-001 (1.0 x 10¹² viral particles) on Day 1 and 15 of each 28-day cycle for up to 12 injections plus a checkpoint inhibitor per investigator discretion.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 79 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: The study is an exploratory open label single-arm interventional study using a 3 + 3 dose escalation safety run-in (PART 1) followed by a dose expansion single-agent (PART 2), followed by expansion (PART 3) single agent or single agent plus checkpoint inhibitor.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects With Refractory Solid Tumors
Actual Study Start Date : March 29, 2021
Estimated Primary Completion Date : March 1, 2023
Estimated Study Completion Date : March 1, 2024

Arm Intervention/treatment
Experimental: PART 1: Dose Escalation Safety Run-In
Subjects will be treated with AdAPT-001 as a single injection, one time.
Biological: AdAPT-001
Oncolytic virus administered by intratumoral injection

Experimental: PART 2: Dose Expansion Single-Agent
6 subjects will be enrolled in the Lead In Cohort. A Safety Analysis will be performed after 6 subjects have received at least 24 doses. Upon Safety team review as a continuous reassessment of safety, an additional 19 subjects may be enrolled. All subjects in PART 2 will receive injections of AdAPT-001 on Days 1 and 15 of 28-day cycles.
Biological: AdAPT-001
Oncolytic virus administered by intratumoral injection

Experimental: PART 3: Expansion
Up to 45 subjects will be enrolled in the expansion cohort to receive either AdAPT-001 on Days 1 and 15 of 28-day cycles or AdAPT-001 on Days 1 and 15 plus a checkpoint inhibitor of 28-day cycles.
Biological: AdAPT-001
Oncolytic virus administered by intratumoral injection

Drug: Checkpoint Inhibitor, Immune
Checkpoint Inhibitor per investigator discretion based on diagnosis and subject tolerability




Primary Outcome Measures :
  1. Dose Limiting Toxicities (DLT) [ Time Frame: 28 days ]
    All subjects in PART 1 will be assessed for the development of dose-limiting toxicity (DLT) during treatment with AdAPT-001. The DLT assessment period is defined as: Day of Injection through 28 days post injection (Safety Follow Up). A DLT will be defined as any Grade 3 or higher adverse event, as assessed by the National Cancer Institute Common Toxicity Criteria for Adverse Events (CTCAE) version 5.0.

  2. Maximum tolerated dose [ Time Frame: 28 days ]
    In PART 1, A MTD is determined if any cohort experiences 2 subjects with DLT's.

  3. Safety of a multiple dose regimen of AdAPT-001 [ Time Frame: 6 months ]
    The safety data will include adverse events, serious adverse events, performance status, clinical laboratory tests, vital signs and physical examination results.


Secondary Outcome Measures :
  1. Anti-tumor activity of AdAPT-001 [ Time Frame: 6 months ]
    In PART 2 and PART 3, overall response rate (ORR) and best overall response rates per response evaluation criteria outlined in Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1), as well as progression-free survival (PFS), and duration of response will be assessed.


Other Outcome Measures:
  1. Anti-tumor activity by iRECIST [ Time Frame: 6 months ]
    ORR and best overall response rates per Immune Response Evaluation Criteria in Solid Tumors (iRECIST)

  2. Biodistribution [ Time Frame: 6 months ]
    This outcome will measure TGFβ trap concentrations in the serum and, in patients who consent to tissue collections, test for TGFβ trap expression in the treated tumors.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is capable of understanding the purpose and risks of the study and has provided written Informed Consent.
  2. Subject is male or female, aged at least 18 years.
  3. Subject has a histologically or cytologically confirmed diagnosis of an advanced malignant solid tumor(s) who have received all conventional therapies considered appropriate by Investigator and have a tumor that is easily accessible and/or palpable for treatment. Ultrasound guidance may be used to aid administration.
  4. Subject's Eastern Cooperative Group (ECOG) performance status is 0-2 at Screening.
  5. Subject has acceptable liver function at Screening, as evidenced by:

    1. Bilirubin < 1.5 x ULN (upper limit of normal)
    2. AST (SGOT) and ALT (SGPT) < 3.0 x ULN (upper limit of normal)
    3. Alkaline Phosphatase < 2.5 x ULN (upper limit of normal)
  6. Subject has a Serum Creatinine < 1.5 x ULN (upper limit of normal)
  7. Subject has acceptable hematologic status at Screening, as evidenced by:

    1. Absolute neutrophil count > 1,500 cells/mm3; > 1.5 x 109/L, and
    2. Platelet count > 75,000/mm3; > 75.0 x 109/L, and
    3. Hemoglobin (HGB) ≥ 8.0 g/dL; ≥ 5.6 mmol/L
  8. Subject has an INR < 1.5
  9. Female subjects of childbearing potential (i.e., women who have not been surgically sterilized or have not been post-menopausal for at least one year), and male subjects with partners of childbearing potential, must agree to use medically acceptable methods of contraception beginning on Study Day 1 and continuing until at least four weeks after administration of the subject's final dose of AdAPT-001. Medically acceptable contraception is defined as either: 1) usage by at least one of the partners of a barrier method of contraception, together with usage by the female partner, commencing at least three months prior to Study Day 1, of a stable regimen of any form of hormonal contraception or an intra-uterine device, or 2) usage by the couple of a double-barrier method of contraception. Use of a single-barrier method alone or abstinence alone is not considered adequate.
  10. Subject is willing and able to comply with all protocol procedures, evaluations and rescue measures.
  11. OPTIONAL: Archival formalin-fixed paraffin-embedded block(s) or previously cut archival tissue for at least 5 unstained slides (if available).

Exclusion Criteria:

  1. Presence of a serious co-morbid medical condition, or a clinically significant laboratory finding(s) that, in the opinion of the Investigator, suggests the presence of an infectious, endocrine, and/or other inadequately treated systemic disorder.
  2. A known uncontrolled active bacterial, fungal, or viral infection. No subject with an active SARS-CoV-2 infection (within 14 days of a positive test)
  3. Known positive history of human immunodeficiency virus (HIV) test
  4. Subjects who have active hepatitis.
  5. If female, subject is pregnant and/or breastfeeding.
  6. Subjects with active autoimmune disease or history of autoimmune disease that might recur and may affect vital organ function or require immune suppressive treatment including systemic corticosteroids, should be excluded.

    Note: Subjects in any condition requiring systemic treatment with corticosteroids (prednisone > 10 mg/day or equivalent of the similar drug) or other immunosuppressive agents within 14 days before AdAPT-001), but currently or previously treated with any of the following steroid regimens were included: Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids with minimal systemic absorption; prophylactic short-term use of corticosteroids.

  7. Prior adenoviral therapy for any indication except vaccination against infectious disease. Subjects receiving COVID-19 or live vaccination, cannot start treatment until 7 days after completing the vaccination. Recommend waiting at least 28 days from AdAPT-001 dose prior to receiving COVID-19 vaccination. Concurrent treatment with Evusheld is allowed.
  8. Chemotherapy or immunotherapy within 14 days of study treatment. Hormonal therapy (including tamoxifen, aromatase inhibitors, and gonadotropin releasing hormone agonists) is allowed. Concurrent treatment with bisphosphonate and RANK ligand inhibitor is allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04673942


Contacts
Layout table for location contacts
Contact: Jeannie Williams 858-947-6644 jwilliams@epicentrx.com

Locations
Layout table for location information
United States, California
City of Hope Recruiting
Duarte, California, United States, 91010
Contact: Victoria Villaflor, MD    877-467-3411      
Principal Investigator: Victoria Villaflor, MD         
California Cancer Associates for Research and Excellence, cCARE Recruiting
San Marcos, California, United States, 92069
Contact: Alberto Bessudo, MD    760-747-8935      
Principal Investigator: Alberto Bessudo, MD         
Providence Saint John's Health Center Recruiting
Santa Monica, California, United States, 90404
Contact: Naveed Wagle, MD    310-582-7448    neuro.research@providence.org   
Principal Investigator: Naveed Wagle, MD         
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
Contact: Brielle Eble    866-223-8100      
Principal Investigator: Brian Gastman, MD         
United States, Texas
Mary Crowley Cancer Research Recruiting
Dallas, Texas, United States, 75230
Contact: Minal Barve, MD    972-566-3000    referral@marycrowley.org   
Principal Investigator: Minal Barve, MD         
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Anthony P Conley, MD         
Principal Investigator: Anthony P Conley, MD         
Sponsors and Collaborators
EpicentRx, Inc.
Investigators
Layout table for investigator information
Study Director: Bryan Oronsky, MD PhD EpicentRx, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: EpicentRx, Inc.
ClinicalTrials.gov Identifier: NCT04673942    
Other Study ID Numbers: BETA-PRIME
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: January 23, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by EpicentRx, Inc.:
oncolytic virus
immunotherapy
adenovirus
intratumoral injection
AdAPT-001
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents